Screener
BioMarin Pharmaceuticals BMRN Business Segments — S&M expenses
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:SellingAndMarketingExpense.
The source filing: BioMarin Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:14 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001048477-26-000016
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Research and early pipeline | 85,069 | 95,968 | 172,360 | 186,438 |
| Later-stage clinical programs | 50,295 | 13,133 | 86,472 | 27,424 |
| Marketed products | 71,588 | 52,207 | 126,916 | 106,177 |
| SG&A expenses | ||||
| S&M expenses | 142,186 | 122,100 | 267,113 | 224,631 |
| G&A expenses | 253,363 | 110,179 | 386,726 | 213,764 |
| Other segment expense, net (1) | 139,650 | 41,201 | 168,246 | 84,255 |
| Net income | $44,762 | $240,532 | $150,289 | $426,218 |
Item 1. Financial Statements
FAQ
- What is BioMarin Pharmaceuticals's business segments — S&M expenses?
- BioMarin Pharmaceuticals (BMRN) reported business segments — S&M expenses of $142.19M in Q2 2026.
- How has BioMarin Pharmaceuticals's business segments — S&M expenses changed year-over-year?
- BioMarin Pharmaceuticals's business segments — S&M expenses increased by 16.5% year-over-year, from $122.1M to $142.19M.
- What is the long-term trend for BioMarin Pharmaceuticals's business segments — S&M expenses?
- Over 3 years (2022 to 2025), BioMarin Pharmaceuticals's business segments — S&M expenses has grown at a 5.6% compound annual growth rate (CAGR), from $450.35M to $530.16M.
- What does business segments — S&M expenses mean?
- This captures the costs associated with sales, marketing, and promotional activities for the products within the reportable segment. It reflects the investment required to educate healthcare providers, support patient access, and drive product adoption. These expenses are critical for maintaining the commercial momentum of rare-disease therapies.
Ask your AI about BioMarin Pharmaceuticals's business segments — s&m expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude